COVID-19 Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D0VI8H
|
|||
| Drug Name |
Ribavirin
|
|||
| Synonyms |
ribavirin; 36791-04-5; Tribavirin; Rebetol; Virazole; Ribavirine; Copegus; Vilona; Ribamide; Ribasphere; Ribamidil; Viramid; Ribamidyl; Ribavirinum; Ribavirina; Rebetron; Varazid; RTCA; Ribavirin Capsules; Ribavirinum [INN-Latin]; Ribavirine [INN-French]; Ribavirina [INN-Spanish]; ICN-1229; Rebretron; Virazid; Ribav; 1-beta-D-Ribofuranosyl-1,2,4-triazole-3-carboxamide; DRG-0028; 1-beta-D-Ribofuranosyl-1H-1,2,4-triazole-3-carboxamide; UNII-49717AWG6K; Ribavirin (Copegus); Copegus; Cotronak; RBV; RTC; Ravanex; Ribacine; Ribovirin; Viramide; Virazide; R 9644; SCH 18908; C-Virin; Copegus (TN); Drug: Ribavirin; KS-1104; R-964; RG-964; Rebetol (TN); Ribasphere (TN); Ribavirin [USAN:INN]; Vilona (TN); Virazole (Ribavirin) Inhalation Solution; Virazole (TN); AA-504/07617051; Ro 20-9963/000; Ro-20-9963; Ribavirin (JAN/USP/INN); 1-beta-D-Ribofuranosyl-1,2,4-triazolo-3-carboxamide; 1-[(2R,3R,4S,5R)-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]-1,2,4-triazole-3-carboxamide; 1-[(2R,3R,4S,5R)-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]-1H-1,2,4-triazole-3-carboxamide; 1-beta-D-ribofuranosyl-1-H-1,2,4-triazole-3-carboxamide; RBI034 (2-5A antisense compound) + Ribavirin
|
|||
| Drug Type |
Small molecular drug
|
|||
| Indication | Coronavirus Disease 2019 (COVID-19) | Investigative | [1] | Middle East Respiratory Syndrome (MERS) | Investigative | [2] | Severe acute respiratory syndrome (SARS) | Investigative | [2], [3] |
| Other Indication | Hepatitis C virus infection | Approved | [4] | |
| Therapeutic Class |
Antiviral Agents
|
|||
| Company |
Hoffmann-La Roche pharmaceutical company
|
|||
| Structure |
 |
Download2D MOL |
||
| Formula |
C8H12N4O5
|
|||
| Canonical SMILES |
C1=NC(=NN1C2C(C(C(O2)CO)O)O)C(=O)N
|
|||
| InChI |
1S/C8H12N4O5/c9-6(16)7-10-2-12(11-7)8-5(15)4(14)3(1-13)17-8/h2-5,8,13-15H,1H2,(H2,9,16)/t3-,4-,5-,8-/m1/s1
|
|||
| InChIKey |
IWUCXVSUMQZMFG-AFCXAGJDSA-N
|
|||
| CAS Number |
CAS 36791-04-5
|
|||
| PubChem Compound ID | ||||
| PubChem Substance ID |
595938, 7847489, 7980513, 8139972, 8150084, 8175073, 11335957, 11361196, 11364740, 11367302, 11369864, 11372951, 11374942, 11378029, 11462168, 11491691, 11493066, 11495640, 11528313, 12059582, 14798456, 15122005, 17389529, 17405619, 24278685, 25621753, 26538475, 26612558, 26679740, 34678832, 46505883, 47291173, 47365228, 47440296, 47515344, 47589035, 47885447, 47885448, 48035157, 48416516, 48424047, 48425596, 48631153, 49699015, 50105410, 50105411, 50105412, 50105413, 50474786, 53778169
|
|||
| ChEBI ID |
CHEBI:63580
|
|||
| Target | Top | |||
|---|---|---|---|---|
| Target(s) | HUMAN inosine-5'-monophosphate dehydrogenase 1 (IMPDH1) | Target Info | Inhibitor | [1] |
| Coronavirus replication depends on availability of cellular nucleotide pools. Compounds interfering with nucleic acid metabolism can inhibit viral replication. Ribavirin, which inhibits inosine monophosphate dehydrogenase (IMPDH), the rate-limiting enzyme in de!novo synthesis of guanosine nucleotides, inhibited SARS-CoV-2 replication at low micromolar and clinically achievable concentrations. | ||||
| HUMAN inosine-5'-monophosphate dehydrogenase 2 (IMPDH2) | Target Info | Inhibitor | [1] | |
| Coronavirus replication depends on availability of cellular nucleotide pools. Compounds interfering with nucleic acid metabolism can inhibit viral replication. Ribavirin, which inhibits inosine monophosphate dehydrogenase (IMPDH), the rate-limiting enzyme in de!novo synthesis of guanosine nucleotides, inhibited SARS-CoV-2 replication at low micromolar and clinically achievable concentrations. | ||||
| MERS-CoV RNA-directed RNA polymerase (RdRp) | Target Info | Inhibitor | [3] | |
| Ribavirin is a nucleoside against MERS-CoV. Its mechanism includes lethal mutagenesis of RNA virus genomes mediated by the MERS-CoV RNA-dependent RNA polymerase. | ||||
| SARS-CoV RNA-directed RNA polymerase (RdRp) | Target Info | Inhibitor | [2], [3] | |
| Ribavirin is a nucleoside against SARS-CoV. Its mechanism includes lethal mutagenesis of RNA virus genomes mediated by the SARS-CoV RNA-dependent RNA polymerase. | ||||
| References | Top | |||
|---|---|---|---|---|
| 1 | Proteomics of SARS-CoV-2-infected Host Cells Reveals Therapy Targets. Nature. 2020 May 14. doi: 10.1038/s41586-020-2332-7. | |||
| 2 | SARS and MERS: recent insights into emerging coronaviruses. Nat Rev Microbiol. 2016 Aug;14(8):523-34. | |||
| 3 | Coronaviruses - drug discovery and therapeutic options. Nat Rev Drug Discov. 2016 May;15(5):327-47. | |||
| 4 | Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. 2015 | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.